Clinical Investigation| Volume 356, ISSUE 4, P365-373, October 2018

The Clinical Impact of Glomerular Immunoglobulin M Deposition in Patients with Type 2 Diabetic Nephropathy



      Glomerular immunoglobulin M (IgM) deposition is common in diabetic kidney disease. The clinical implication of IgM deposition in the renal tissues of type 2 diabetes mellitus patients with biopsy-proven diabetic nephropathy remains unclear.

      Materials and Methods

      One hundred thirty-two patients with type 2 diabetes and biopsy-proven pure diabetic nephropathy were enrolled retrospectively. Clinicopathological features and renal outcomes were compared between patients with and without glomerular capillary IgM deposition. A Cox proportional hazards model was employed to identify the risk factors associated with renal survival.


      Fifty-two patients had positive linear glomerular capillary IgM staining. Patients with glomerular capillary IgM deposition presented with heavier proteinuria, and lower serum albumin. During 35.5 (12, 107) months of follow-up, patients with glomerular tuft IgM deposition had shorter renal survival than those with negative IgM deposition (39 [23.74, 54.26] versus (vs.) 64 [45.82, 82.18] months, P = 0.01). Patients with glomerular complement 1q (C1q) deposition showed worse renal survival than those lacking glomerular C1q deposition (36 [23.82, 48.18] vs. 60 [50.27, 69.74] months, P = 0.001). Worse renal outcome was observed in patients with glomerular C3 deposition than in those without glomerular C3 deposition (37 [22.43, 51.56] vs. 63 [51.75, 74.25] months, P = 0.001). Multivariate Cox proportional analysis demonstrated that combined glomerular capillary IgM and C1q deposition was an independent predictor of end-stage renal disease (hazard ratio 3.75, 95% CI[ 1.68,8.35], P = 0.001).


      Patients with diabetic nephropathy and combined glomerular capillary IgM and C1q deposition had unfavorable renal outcome, which indicates that IgM derived from B cells might be involved in diabetic kidney injury.

      Key Indexing Terms

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Retnakaran R
        • Cull CA
        • Thorne KI
        • et al.
        Risk factors for renal dysfunction in type 2 diabetes: U.K. prospective diabetes study 74.
        Diabetes. 2006; 55: 1832-1839
        • Fioretto P
        • Mauer M
        • Brocco E
        • et al.
        Patterns of renal injury in NIDDM patients with microalbuminuria.
        Diabetologia. 1996; 39: 1569-1576
        • Sharma SG
        • Bomback AS
        • Radhakrishnan J
        • et al.
        The modern spectrum of renal biopsy findings in patients with diabetes.
        Clin J Am Soc Nephrol. 2013; 8: 1718-1724
        • Thomas MC
        • Cooper ME
        Zimmet P Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease.
        Nat Rev Nephrol. 2016; 12: 73-81
        • Tervaert TW
        • Mooyaart AL
        • Amann K
        • et al.
        Pathologic classification of diabetic nephropathy.
        J Am Soc Nephrol. 2010; 21: 556-563
        • Mise K
        • Hoshino J
        • Ubara Y
        • et al.
        Renal prognosis a long time after renal biopsy on patients with diabetic nephropathy.
        Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association. 29. European Renal Association, 2014: 109-118
        • An Y
        • Xu F
        • Le W
        • et al.
        Renal histologic changes and the outcome in patients with diabetic nephropathy.
        Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association. 30. European Renal Association, 2015: 257-266
        • Mise K
        • Hoshino J
        • Ueno T
        • et al.
        Clinical implications of linear immunofluorescent staining for immunoglobulin G in patients with diabetic nephropathy.
        Diabetes Res Clin Pract. 2014; 106: 522-530
        • Fujita T
        • Ohi H
        • Komatsu K
        • et al.
        Complement activation accelerates glomerular injury in diabetic rats.
        Nephron. 1999; 81: 208-214
        • Levey AS
        • Stevens LA
        • Schmid CH
        • et al.
        A new equation to estimate glomerular filtration rate.
        Ann Intern Med. 2009; 150: 604-612
        • Ainsworth SK
        • Hirsch HZ
        • Brackett Jr., NC
        • et al.
        Diabetic glomerulonephropathy: histopathologic, immunofluorescent, and ultrastructural studies of 16 cases.
        Hum Pathol. 1982; 13: 470-478
        • Connor TM
        • Aiello V
        • Griffith M
        • et al.
        The natural history of immunoglobulin M nephropathy in adults.
        Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association. 32. European Renal Association, 2017: 823-829
        • Zhang YM
        • Gu QH
        • Huang J
        • et al.
        Clinical significance of IgM and C3 glomerular deposition in primary focal segmental glomerulosclerosis.
        Clin J Am Soc Nephrol. 2016; 11: 1582-1589
        • Melez KA
        • Harrison LC
        • Gilliam JN
        • et al.
        Diabetes is associated with autoimmunity in the New Zealand obese (NZO) mouse.
        Diabetes. 1980; 29: 835-840
      1. Yamada N, Hashimoto N, Kamiie J, et al. Relationship between immunoglobulin deposition and early lesions of progressive glomerulonephropathy in young common marmosets. Vet Pathol. 2018;55:173–6.

        • Nikolov A
        • Tsinlikov I
        • Tsinlikova I
        • et al.
        Serum anti-collagen type IV IgM antibodies and development of diabetic nephropathy in diabetics with essential hypertension.
        Cent Eur J Immunol. 2016; 41: 86-92
        • Panzer SE
        • Laskowski J
        • Renner B
        • et al.
        IgM exacerbates glomerular disease progression in complement-induced glomerulopathy.
        Kidney Int. 2015; 88: 528-537
        • Tofik R
        • Torffvit O
        • Rippe B
        • et al.
        Urine IgM-excretion as a prognostic marker for progression of type 2 diabetic nephropathy.
        Diabetes Res Clin Pract. 2012; 95: 139-144
        • Bakoush O
        • Tencer J
        • Tapia J
        • et al.
        Higher urinary IgM excretion in type 2 diabetic nephropathy compared to type 1 diabetic nephropathy.
        Kidney Int. 2002; 61: 203-208
        • Moon JY
        • Jeong KH
        • Lee TW
        • et al.
        Aberrant recruitment and activation of T cells in diabetic nephropathy.
        Am J Nephrol. 2012; 35: 164-174
        • Winer DA
        • Winer S
        • Shen L
        • et al.
        B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies.
        Nat Med. 2011; 17: 610-617
        • DeFuria J
        • Belkina AC
        • Jagannathan-Bogdan M
        • et al.
        B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile.
        Proc Natl Acad Sci USA. 2013; 110: 5133-5138
        • Winer S
        • Chan Y
        • Paltser G
        • et al.
        Normalization of obesity-associated insulin resistance through immunotherapy.
        Nat Med. 2009; 15: 921-929
        • Pescovitz MD
        • Greenbaum CJ
        • Krause-Steinrauf H
        • et al.
        Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
        N Engl J Med. 2009; 361: 2143-2152
        • Hu CY
        • Rodriguez-Pinto D
        • Du W
        • et al.
        Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice.
        J Clin Invest. 2007; 117: 3857-3867
        • Kim HN
        • Fesseha B
        • Anzaldi L
        • et al.
        Antibody-mediated extreme insulin resistance: a report of three cases.
        Am J Med. 2018; 131: 102-106
        • Zwirner J
        • Felber E
        • Herzog V
        • et al.
        Classical pathway of complement activation in normal and diseased human glomeruli.
        Kidney Int. 1989; 36: 1069-1077
        • Strassheim D
        • Renner B
        • Panzer S
        • et al.
        IgM contributes to glomerular injury in FSGS.
        J Am Soc Nephrol. 2013; 24: 393-406
        • Watanabe S
        Histopathological and immunopathological studies on renal involvement in non-obese diabetic (NOD) mice.
        Nihon Jinzo Gakkai shi. 1989; 31: 1011-1019
        • Kelly KJ
        • Liu Y
        • Zhang J
        • et al.
        Renal C3 complement component: feed forward to diabetic kidney disease.
        Am J Nephrol. 2015; 41: 48-56
        • Li L
        • Chen L
        • Zang J
        • et al.
        C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt/beta-catenin signaling pathway in diabetic kidney disease.
        Metabolism. 2015; 64: 597-610